Insider Selling: Sera Prognostics (NASDAQ:SERA) CEO Sells 20,755 Shares of Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,755 shares of the stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $2.08, for a total transaction of $43,170.40. Following the completion of the transaction, the chief executive officer directly owned 871,999 shares of the company’s stock, valued at $1,813,757.92. The trade was a 2.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Down 6.1%

Shares of Sera Prognostics stock traded down $0.13 during midday trading on Wednesday, hitting $2.00. The company had a trading volume of 99,259 shares, compared to its average volume of 58,147. The stock has a market cap of $78.32 million, a price-to-earnings ratio of -3.08 and a beta of 0.94. The company has a fifty day simple moving average of $2.03 and a 200 day simple moving average of $2.56. Sera Prognostics, Inc. has a 12-month low of $1.43 and a 12-month high of $4.09.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Sera Prognostics had a negative net margin of 56,385.97% and a negative return on equity of 41.02%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.07 million. As a group, analysts expect that Sera Prognostics, Inc. will post -0.58 EPS for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of institutional investors have recently added to or reduced their stakes in SERA. Qube Research & Technologies Ltd acquired a new stake in Sera Prognostics in the 2nd quarter valued at $92,000. Captrust Financial Advisors grew its stake in Sera Prognostics by 20.0% in the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after acquiring an additional 100,366 shares during the period. Corient Private Wealth LLC grew its stake in Sera Prognostics by 73.9% in the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock valued at $277,000 after acquiring an additional 42,500 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new stake in Sera Prognostics in the 3rd quarter valued at $38,000. Finally, Caprock Group LLC acquired a new stake in Sera Prognostics in the 3rd quarter valued at $108,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a research note on Friday, March 27th. Craig Hallum assumed coverage on shares of Sera Prognostics in a research note on Thursday, June 4th. They set a “buy” rating and a $6.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.